🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1 result for “Tivicay” Clear

  1. Ziagen 300 mg film-coated tablets, INTELENCE 200 mg tablets, Eviplera 200 mg/25 mg/245 mg film-coated tablets, EDURANT 25 mg film-coated tablets, Telzir 700 mg film-coated tablets, TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets, Delstrigo 100 mg/300 mg/245 mg film-coated tablets, Norvir 100 mg film-coated tablets, Ritonavir Accord 100 mg filmomhulde tabletten, Descovy 200 mg/10 mg film-coated tablets, REYATAZ 300 mg hard capsules, REKAMBYS 600 mg prolonged-release suspension for injection, Tivicay 50 mg

    Disc Medicine

    HIV-infected

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources